Key result
The abstract reports clinical experience from the RIETE registry concerning the relationship between different platelet values and bleeding risk in VTE patients on anticoagulants, without providing quantitative results.
Why the study?
Major bleeding is a dangerous complication of anticoagulant treatment for VTE, and risk scores commonly consider platelet count, particularly thrombocytopenia.
Does platelet count affect the risk of bleeding in patients receiving anticoagulant therapy for venous thromboembolism?
Observational
Does platelet count affect the risk of bleeding in patients receiving anticoagulant therapy for venous thromboembolism?
Answers are grounded in this paper and cite their sources.
Should not yet guide platelet-based anticoagulation adjustments in VTE; hypothesis-generating observational data needing prospective validation.
Major bleeding is one of the most dangerous complications for patients undergoing anticoagulant treatment for VTE. Several clinical scores have been planned to identify patients at higher risk of bleeding, and most of them take into consideration the number of platelets in particular if lower than normal. Here we report the clinical experience made with the RIETE registry concerning anticoagulant treatment in the presence of different values of platelets and their related risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Micco et al. (2020) conducted an observational in Venous Thromboembolism (VTE). Different values of platelets was evaluated on Risk of bleeding. The abstract reports clinical experience from the RIETE registry concerning the relationship between different platelet values and bleeding risk in VTE patients on anticoagulants, without providing quantitative results.
Synapse has enriched 10 related papers. Consider them for comparative context: